Letter to the Editor
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs and/or Biological DMARDs: Data from a Local Registry
Eficacia y seguridad de baricitinib en pacientes con artritis reumatoide y respuesta inadecuada a FAME convencionales sintéticos o biológicos: datos de un registro local
Leído
4398
Vecesse ha leído el artículo
1577
Total PDF
2821
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 52 | 27 | 79 |
| 2025 11 | 349 | 74 | 423 |
| 2025 10 | 20 | 73 | 93 |
| 2025 9 | 0 | 72 | 72 |
| 2025 8 | 0 | 51 | 51 |
| 2025 7 | 0 | 41 | 41 |
| 2025 6 | 2 | 25 | 27 |
| 2025 5 | 131 | 91 | 222 |
| 2025 4 | 120 | 52 | 172 |
| 2025 3 | 99 | 34 | 133 |
| 2025 2 | 85 | 48 | 133 |
| 2025 1 | 70 | 39 | 109 |
| 2024 12 | 55 | 32 | 87 |
| 2024 11 | 45 | 68 | 113 |
| 2024 10 | 42 | 35 | 77 |
| 2024 9 | 58 | 23 | 81 |
| 2024 8 | 72 | 46 | 118 |
| 2024 7 | 73 | 30 | 103 |
| 2024 6 | 67 | 29 | 96 |
| 2024 5 | 104 | 30 | 134 |
| 2024 4 | 67 | 24 | 91 |
| 2024 3 | 66 | 28 | 94 |
| 2024 2 | 87 | 25 | 112 |
| 2024 1 | 85 | 23 | 108 |
| 2023 12 | 64 | 35 | 99 |
| 2023 11 | 93 | 43 | 136 |
| 2023 10 | 69 | 33 | 102 |
| 2023 9 | 132 | 39 | 171 |
| 2023 8 | 50 | 21 | 71 |
| 2023 7 | 60 | 27 | 87 |
| 2023 6 | 74 | 39 | 113 |
| 2023 5 | 57 | 24 | 81 |
| 2023 4 | 41 | 22 | 63 |
| 2023 3 | 69 | 37 | 106 |
| 2023 2 | 54 | 28 | 82 |
| 2022 1 | 42 | 21 | 63 |
| 2022 12 | 68 | 42 | 110 |
| 2022 11 | 60 | 38 | 98 |
| 2022 10 | 59 | 39 | 98 |
| 2022 9 | 65 | 64 | 129 |
| 2022 8 | 4 | 3 | 7 |
| 2022 5 | 1 | 2 | 3 |
| 2022 4 | 2 | 0 | 2 |
| 2022 2 | 7 | 0 | 7 |
| 2021 7 | 1 | 0 | 1 |
Mostrar todo
